TG Therapeutics, Inc. (NASDAQ:TGTX) went up to recover about 97.56% since recording its record low price of $4.10. The stock experienced 6.58% jump, arriving at $8.1 on 11/28/2017. During the day, the stock price traveled from $7.55 to $8.2. This company shares are 255.56% off its target price of $28.8 and the current market capitalization stands at $549.83M. The recent change has given its price a -15.09% deficit over SMA 50 and -47.23% deficit over its 52-week high. The stock witnessed -0.61% declines, -33.06% declines and -28% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TGTX’s volatility during a week at 6.21% and during a month it has been found around 6.24%.TG Therapeutics, Inc. (TGTX) Top Holders
Institutional investors currently hold around $271 million or 57.1% in TGTX stock. Look at its top three institutional owners. Fmr Llc owns $49.03 million in TG Therapeutics, Inc., which represents roughly 8.92% of the company’s market cap and approximately 18.09% of the institutional ownership. Similar statistics are true for the second largest owner, Bridger Management, Llc, which owns 5,295,044 shares of the stock are valued at $40.24 million. The third largest holder is Blackrock Inc., which currently holds $25.08 million worth of this stock and that ownership represents nearly 4.56% of its market capitalization.TG Therapeutics, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 41 institutional holders increased their position in TG Therapeutics, Inc. (NASDAQ:TGTX) by some 2,582,987 shares, 39 decreased positions by 1,321,136 and 32 held positions by 31,727,497. That puts total institutional holdings at 35,631,620 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 43,823 shares while 12 institutional investors sold out their entire positions totaling 461,331 shares.TG Therapeutics, Inc. (NASDAQ:TGTX) Insider Trades
Multiple company employees have indulged in significant insider trading. TG Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO, Secretary and Treasurer Power Sean A has sold 59,976 shares of TG Therapeutics, Inc. (TGTX) in trading session dated Jun. 19, 2017. These shares are worth $665,134 and were traded at $11.09 each. The SEC filing shows that Kennedy William James performed a sale of 8,548 shares. The Director disposed these shares by way of transaction on Apr. 11, 2017. The company’s shares were given away at $10.27 per share worth to an income of some $87,788 on account of Kennedy William James.
Director, Charney Laurence N, sold 7,000 common shares of TG Therapeutics, Inc. (TGTX) in the open market. In a transaction dated Apr. 04, 2017, the shares were put up for sale at an average price of $11.17, raking in a sum of $78,190. After this sale, 88,949 common shares of TGTX are directly owned by the insider, with total stake valued at $720,487.
In the transaction dated Jan. 04, 2017, the great number of shares disposed came courtesy the CFO, Secretary and Treasurer; Power Sean A disposed a total of 8,816 shares at an average price of $4.55, amounting to approximately $40,113. The insider now directly owns 507,440 shares worth $4,110,264.TG Therapeutics, Inc. (TGTX) Analyst Guide
Several analysts have released their opinion on TG Therapeutics, Inc. (NASDAQ:TGTX), with 5 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.